New drug combo targets tough pancreatic cancer in early trial

NCT ID NCT06059001

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called OMO-103, which blocks a cancer-driving protein called MYC, combined with standard chemotherapy in 26 people with metastatic pancreatic cancer who have not had prior treatment for advanced disease. The main goals are to check safety and how well the body handles the drug, while also looking for signs that tumors shrink or stop growing. This is not a cure, but aims to better control the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm Neoplasm Metastasis pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Gregorio Marañon

    Madrid, Madrid, 28007, Spain

  • Hospital Miguel Servet

    Zaragoza, Zaragoza, 5009, Spain

  • Hospital Regional Universitario de Málaga

    Málaga, Spain, 29010, Spain

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, 39008, Spain

  • Hospital Vall d´Hebrón

    Barcelona, Barcelona, 08035, Spain

  • ICO Hopsitalet

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain